Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Genmab A/S | EPCORE - (NHL-6) | Non-Hodgkin Lymphoma (NHL) | Phase 2 | Intravenous | Oncology | |
| Genmab A/S | MCLA-129 - (ZENO) | Solid Tumors, MET ex14 NSCLC | Phase 3 | Data Released | Intravenous | Oncology |
| Genmab A/S | Acasunlimab (DuoBody-PD-L1x4-1BB) with pembrolizumab | Metastatic non-small cell lung cancer (mNSCLC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Genmab A/S | EPKINLY (epcoritamab-bysp) in combination with standard-of-care rituximab (R-CHOP) - (DLBCL-2) | Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) | Phase 3 | Ongoing | Subcutaneous | Oncology |
| Genmab A/S | Petosemtamab (MCLA-158) | Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors | Phase 2 | Data Released | Intravenous | Oncology |
| Genmab A/S | EPKINLY (epcoritamab-bysp) - (DLBCL-1 ) | Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) | Phase 3 | Data Released | Subcutaneous | Oncology |
| Genmab A/S | Zenocutuzumab (Zeno) in combination with Trastuzumab and Vinorelbine | Metastatic breast cancer | Phase 2 | Data Released | Intravenous | Oncology |
| Genmab A/S | EPKINLY (epcoritamab-bysp) in combination with lenalidomide versus chemo-immunotherapy - (DLBCL-4) | Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) | Phase 3 | Ongoing | Subcutaneous | Oncology |
